Skip Navigation



Annals of Oncology Advance Access published online on January 30, 2006
Annals of Oncology, doi:10.1093/annonc/mdl002
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/4/676    most recent
mdl002v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gobbi, P. G.
Right arrow Articles by Federico, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gobbi, P. G.
Right arrow Articles by Federico, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received November 4, 2005
Revised December 10, 2005
Accepted December 21, 2005

original article

The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: A randomized trial by the Gruppo Italiano Studio Linfomi (GISL)

P. G. Gobbi 1 *, C. Broglia 1, F. Valentino 1, C. Mammi 2, M. Lombardo 3, F. Merli 4, S. Luminari 2, G. Polimeno 5, A. Riezzo 6, P. Lambelet 7, A. Rovati 8, G. R. Corazza 1, and M. Federico 2

1 Medicina Interna, Oncologia e Gastroenterologia, Università di Pavia, IRCCS Policlinico S. Matteo, Pavia
2 Sez. di Oncologia, Università di Modena e Reggio E., Policlinico di Modena
3 Dip. di Oncologia, Ospedale S. Spirito, Pescara
4 Serv. di Ematologia, Arcispedale ‘S. Maria Nuova’, Reggio Emilia
5 Serv. di Ematologia, Div. di Medicina, Ospedale ‘Miulli’, Acquaviva delle Fonti (BA)
6 Div. di Ematologia, Ospedale ‘S. Nicola Pellegrino’, Trani (BA)
7 Div. di Medicina, Ospedale di Viareggio (PI)
8 Sez. di Ematologia, Medina I, Ospedale Maggiore, Lodi, Italy

* To whom correspondence should be addressed.
P. G. Gobbi, E-mail: gobbipg{at}smatteo.pv.it


  Abstract

Background: It is still unclear the actual contribute of dose intensity (DI), dose size (DS) and dose density (DD) in the conventional chemotherapy of large, B-cell non-Hodgkin lymphomas.

Methods: A prospective, randomized trial compared the cyclic schedule of ProMECE-CytaBOM chemotherapy (cyc-PC, 6 cycles) with a modified version of it, which administered the same drugs sequentially (seq-PC), with the same planned cumulative DI and an 83% DD, within the same time frame (113 days), but with three times higher DS of all the drugs except vincristine.

Results: Fifty-six patients received cyc-PC and 52 seq-PC. The actual mean cumulative DI was 0.79 ± 0.15 with cyc-PC, 0.78 ± 0.17 with seq-PC. Response was complete in 59% and 52%, partial in 20% and 21%, null in 5% and 6%, respectively. There were four toxic deaths (two per arm). Relapses occurred in 36% and 37%, respectively. Toxicity was similar in both arms. Overall, failure-free, progression-free and disease-free survival (median follow-up: 54 months) were statistically indifferent.

Conclusions: The very similar DI actually delivered in both arm seems to be the main common determinant of the indifferent results recorded. Increasing DS - at least within the limits clinically attainable without stem cell rescue - does not improve results.

Keywords: chemotherapy; large B-cell lymphoma; dose intensity; dose size; dose density.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Bari, L. Marcheselli, S. Sacchi, R. Marcheselli, S. Pozzi, P. Ferri, E. Balleari, P. Musto, S. Neri, M. A. Aloe Spiriti, et al.
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story
Ann. Onc., November 17, 2009; (2009) mdp531v1.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
S. Sacchi, L. Marcheselli, A. Bari, R. Marcheselli, S. Pozzi, P. G. Gobbi, F. Angrilli, M. Brugiatelli, P. Musto, and M. Federico
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study
Haematologica, September 1, 2008; 93(9): 1335 - 1342.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.